Literature DB >> 17051362

[Juvenile dermatomyositis].

F Dressler1, H-I Huppertz.   

Abstract

Juvenile dermatomyositis (JDM) is an inflammatory multi-system disease of unknown etiology with classic involvement of the skin and striated muscles. Following a prodromal period, patients develop a progressive proximal muscle weakness. Typical skin involvement includes heliotrope rash, facial erythema, Gottron's sign and nailfold capillary abnormalities. For the diagnosis of JDM, modified Bohan and Peter criteria are used including clinical skin and muscle signs plus elevated muscle enzymes and typical findings from electromyography, muscle biopsy and - more recently - also on magnetic resonance imaging. Steroids are administered classically as high-dose oral treatment. Intravenous pulse therapy with intermittent lower dose oral treatment and other immunosuppressive drugs such as methotrexate may reduce steroid side-effects. Prognosis in JDM has improved, and most patients eventually make a full functional recovery. However, a few patients still die from their disease, and in a minority significant sequelae with muscle atrophy or severe calcinosis ensue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051362     DOI: 10.1007/s00393-006-0109-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  18 in total

1.  What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis?

Authors:  J C Wargula; D J Lovell; M H Passo; K E Bove; J D Santangelo; J E Levinson
Journal:  Clin Exp Rheumatol       Date:  2006 May-Jun       Impact factor: 4.473

2.  Study of subcutaneous fat in children with juvenile dermatomyositis.

Authors:  Sumit Verma; Surjit Singh; Anil Kumar Bhalla; Madhu Khullar
Journal:  Arthritis Rheum       Date:  2006-08-15

3.  Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy.

Authors:  Maryam Y Naim; Ann M Reed
Journal:  J Rheumatol       Date:  2006-07       Impact factor: 4.666

4.  The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.

Authors:  L J McCann; A D Juggins; S M Maillard; L R Wedderburn; J E Davidson; K J Murray; C A Pilkington
Journal:  Rheumatology (Oxford)       Date:  2006-03-27       Impact factor: 7.580

5.  Leptin-replacement therapy for lipodystrophy.

Authors:  Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

Review 6.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.

Authors:  Nicolino Ruperto; Angelo Ravelli; Kevin J Murray; Daniel J Lovell; Boel Andersson-Gare; Brian M Feldman; Stella Garay; Wietse Kuis; Claudia Machado; Lauren Pachman; Anne-Marie Prieur; Lisa G Rider; Earl Silverman; Elena Tsitsami; Pat Woo; Edward H Giannini; Alberto Martini
Journal:  Rheumatology (Oxford)       Date:  2003-06-27       Impact factor: 7.580

7.  Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis.

Authors:  W E Crowe; K E Bove; J E Levinson; P K Hilton
Journal:  Arthritis Rheum       Date:  1982-02

8.  The incidence of juvenile dermatomyositis: results from a nation-wide study.

Authors:  D P Symmons; J A Sills; S M Davis
Journal:  Br J Rheumatol       Date:  1995-08

9.  Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.

Authors:  Adam M Huber; Brian M Feldman; Robert M Rennebohm; Jeanne E Hicks; Carol B Lindsley; Maria D Perez; Lawrence S Zemel; Carol A Wallace; Susan H Ballinger; Murray H Passo; Ann M Reed; Ronald M Summers; Patience H White; Ildy M Katona; Frederick W Miller; Peter A Lachenbruch; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2004-05

10.  Duration of illness is an important variable for untreated children with juvenile dermatomyositis.

Authors:  Lauren M Pachman; Kathy Abbott; James M Sinacore; Lisa Amoruso; Alan Dyer; Rebecca Lipton; Norman Ilowite; Christine Hom; Gail Cawkwell; Andrew White; Rafael Rivas-Chacon; Yukiko Kimura; Linda Ray; Rosalind Ramsey-Goldman
Journal:  J Pediatr       Date:  2006-02       Impact factor: 4.406

View more
  5 in total

Review 1.  [Juvenile dermatomyositis-what's new?]

Authors:  C Hinze
Journal:  Z Rheumatol       Date:  2019-09       Impact factor: 1.372

Review 2.  [Dermatomyositis and juvenile dermatomyositis].

Authors:  Frank Dressler; Britta Maurer
Journal:  Z Rheumatol       Date:  2022-04-29       Impact factor: 1.372

3.  Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.

Authors:  Claas H Hinze; Fabian Speth; Prasad T Oommen; Johannes-Peter Haas
Journal:  Pediatr Rheumatol Online J       Date:  2018-06-20       Impact factor: 3.054

4.  Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.

Authors:  Claas H Hinze; Prasad T Oommen; Frank Dressler; Andreas Urban; Frank Weller-Heinemann; Fabian Speth; Elke Lainka; Jürgen Brunner; Heike Fesq; Dirk Foell; Wolfgang Müller-Felber; Ulrich Neudorf; Christoph Rietschel; Tobias Schwarz; Ulrike Schara; Johannes-Peter Haas
Journal:  Pediatr Rheumatol Online J       Date:  2018-06-25       Impact factor: 3.054

5.  Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.

Authors:  Fabian Speth; Johannes-Peter Haas; Claas H Hinze
Journal:  Pediatr Rheumatol Online J       Date:  2016-09-13       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.